U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Decreased circulating follicle stimulating hormone concentration

MedGen UID:
892977
Concept ID:
C4072889
Finding
Synonym: Decreased circulating follicle stimulating hormone level
 
HPO: HP:0030341

Definition

A reduction of the circulating level of follicle-stimulating hormone (FSH). [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVDecreased circulating follicle stimulating hormone concentration

Conditions with this feature

Pituitary hormone deficiency, combined, 2
MedGen UID:
209236
Concept ID:
C0878683
Disease or Syndrome
PROP1-related combined pituitary hormone deficiency (CPHD) is associated with deficiencies of: growth hormone (GH); thyroid-stimulating hormone (TSH); the two gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH); prolactin (PrL); and occasionally adrenocorticotropic hormone (ACTH). At birth, in contrast to individuals with congenital CPHD of other etiologies, neonates with PROP1-related CPHD lack perinatal signs of hypopituitarism. Mean birth weights and lengths are usually within the normal range and neonatal hypoglycemia and prolonged neonatal jaundice are not prevalent findings. Most affected individuals are ascertained because of short stature during childhood. Although TSH deficiency can present shortly after birth, TSH deficiency usually occurs with or after the onset of GH deficiency. Hypothyroidism is usually mild. FSH and LH deficiencies are typically identified at the age of onset of puberty. Affected individuals can have absent or delayed and incomplete secondary sexual development with infertility. Untreated males usually have a small penis and small testes. Some females experience menarche but subsequently require hormone replacement therapy. ACTH deficiency is less common and, when present, usually occurs in adolescence or adulthood. Neuroimaging of hypothalamic-pituitary region usually demonstrates a hypoplastic or normal anterior pituitary lobe and a normal posterior pituitary lobe.
Hypogonadotropic hypogonadism 1 with or without anosmia
MedGen UID:
295872
Concept ID:
C1563719
Disease or Syndrome
Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.
Kallmann syndrome with spastic paraplegia
MedGen UID:
333437
Concept ID:
C1839911
Disease or Syndrome
Ataxia-hypogonadism-choroidal dystrophy syndrome
MedGen UID:
347798
Concept ID:
C1859093
Disease or Syndrome
PNPLA6 disorders span a phenotypic continuum characterized by variable combinations of cerebellar ataxia; upper motor neuron involvement manifesting as spasticity and/or brisk reflexes; chorioretinal dystrophy associated with variable degrees of reduced visual function; and hypogonadotropic hypogonadism (delayed puberty and lack of secondary sex characteristics). The hypogonadotropic hypogonadism occurs either in isolation or as part of anterior hypopituitarism (growth hormone, thyroid hormone, or gonadotropin deficiencies). Common but less frequent features are peripheral neuropathy (usually of axonal type manifesting as reduced distal reflexes, diminished vibratory sensation, and/or distal muscle wasting); hair anomalies (long eyelashes, bushy eyebrows, or scalp alopecia); short stature; and impaired cognitive functioning (learning disabilities in children; deficits in attention, visuospatial abilities, and recall in adults). Some of these features can occur in distinct clusters on the phenotypic continuum: Boucher-Neuhäuser syndrome (cerebellar ataxia, chorioretinal dystrophy, and hypogonadotropic hypogonadism); Gordon Holmes syndrome (cerebellar ataxia, hypogonadotropic hypogonadism, and – to a variable degree – brisk reflexes); Oliver-McFarlane syndrome (trichomegaly, chorioretinal dystrophy, short stature, intellectual disability, and hypopituitarism); Laurence-Moon syndrome; and spastic paraplegia type 39 (SPG39) (upper motor neuron involvement, peripheral neuropathy, and sometimes reduced cognitive functioning and/or cerebellar ataxia).
Delayed puberty, self-limited
MedGen UID:
1789612
Concept ID:
C2874202
Disease or Syndrome
Self-limited delayed puberty (DPSL) is characterized by delayed development of Tanner stage G2 accompanied by low serum gonadotropins. Affected individuals experience spontaneous attainment of Tanner stage G4 by 18 years of age, with normalization of gonadotropins, which excludes a diagnosis of hypogonadotropic hypogonadism (see 147950) (Mancini et al., 2020).
Pituitary hormone deficiency, combined, 6
MedGen UID:
462790
Concept ID:
C3151440
Disease or Syndrome
Any combined pituitary hormone deficiencies, genetic form in which the cause of the disease is a mutation in the OTX2 gene.
Hypogonadotropic hypogonadism 13 with or without anosmia
MedGen UID:
762090
Concept ID:
C3541462
Disease or Syndrome
Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.
Hypogonadotropic hypogonadism 8 with or without anosmia
MedGen UID:
766755
Concept ID:
C3553841
Disease or Syndrome
Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.
Hypogonadotropic hypogonadism 10 with or without anosmia
MedGen UID:
766757
Concept ID:
C3553843
Disease or Syndrome
Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.
Hypogonadotropic hypogonadism 16 with or without anosmia
MedGen UID:
766935
Concept ID:
C3554021
Disease or Syndrome
Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.
Hypogonadotropic hypogonadism 22 with or without anosmia
MedGen UID:
863425
Concept ID:
C4014988
Disease or Syndrome
Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., <4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.
BDV syndrome
MedGen UID:
1785671
Concept ID:
C5543403
Disease or Syndrome
BDV syndrome (BDVS) is an autosomal recessive disorder characterized by early-onset profound obesity, hyperphagia, and moderately impaired intellectual development accompanied by infantile hypotonia and other endocrine disorders including hypogonadotropic hypogonadism, hypothyroidism, and insulin resistance (summary by Bosch et al., 2021).
Hypogonadotropic hypogonadism 24 without anosmia
MedGen UID:
1806136
Concept ID:
C5574957
Disease or Syndrome
Congenital idiopathic hypogonadotropic hypogonadism (IHH) is a disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. Idiopathic hypogonadotropic hypogonadism can be caused by an isolated defect in gonadotropin-releasing hormone (GNRH; 152760) release, action, or both. Other associated nonreproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss, occur with variable frequency. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism has been called 'Kallmann syndrome (KS),' whereas in the presence of a normal sense of smell, it has been termed 'normosmic idiopathic hypogonadotropic hypogonadism (nIHH)' (summary by Raivio et al., 2007). Because families have been found to segregate both KS and nIHH, the disorder is here referred to as 'hypogonadotropic hypogonadism with or without anosmia (HH).' For a general phenotypic description and a discussion of genetic heterogeneity of hypogonadotropic hypogonadism with or without anosmia, see 147950.
Hypogonadotropic hypogonadism 27 without anosmia
MedGen UID:
1810165
Concept ID:
C5676921
Disease or Syndrome
Hypogonadotropic hypogonadism-27 without anosmia (HH27) is characterized by lack of pubertal development associated with onset of obesity in early adolescence (Topaloglu et al., 2022). Congenital idiopathic hypogonadotropic hypogonadism (IHH) is a disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. Idiopathic hypogonadotropic hypogonadism can be caused by an isolated defect in gonadotropin-releasing hormone (GNRH; 152760) release, action, or both. Other associated nonreproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss, occur with variable frequency. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism has been called 'Kallmann syndrome (KS),' whereas in the presence of a normal sense of smell, it has been termed 'normosmic idiopathic hypogonadotropic hypogonadism (nIHH)' (summary by Raivio et al., 2007). Because families have been found to segregate both KS and nIHH, the disorder is here referred to as 'hypogonadotropic hypogonadism with or without anosmia (HH).'
Cerebellar dysfunction, impaired intellectual development, and hypogonadotropic hypogonadism
MedGen UID:
1808634
Concept ID:
C5676924
Disease or Syndrome
Cerebellar dysfunction, impaired intellectual development, and hypogonadotropic hypogonadism (CDIDHH) is characterized by delayed motor development, ataxia, severe progressive scoliosis, moderate to severe intellectual disability, and delayed sexual development. Cerebellar hypoplasia has been observed in some patients (Whittaker et al., 2021).
Pituitary hormone deficiency, combined or isolated, 8
MedGen UID:
1841011
Concept ID:
C5830375
Disease or Syndrome
Combined pituitary hormone deficiency-8 (CPHD8) is an autosomal dominant disorder characterized by deficiency of one or more of the pituitary hormones. Affected individuals have short stature due to growth hormone (GH; 139250) deficiency with variable deficiencies of other pituitary hormones, including TSH (see 188540), ACTH, and LH/FSH (see 118850). Posterior pituitary deficiency leading to central diabetes insipidus is rare (Bashamboo et al., 2017). Many patients are diagnosed with 'pituitary stalk interruption syndrome' (PSIS), which is characterized by a thin or absent pituitary stalk, absent or ectopic posterior pituitary, and hypoplasia of the anterior pituitary demonstrated on brain imaging, although this classic triad may be incomplete. Brauner et al. (2020) noted the complex phenotypic and genetic heterogeneity of PSIS, and concluded that it is a feature of genetic disorders or syndromes rather than a specific clinical entity. For a discussion of genetic heterogeneity of combined pituitary hormone deficiency, see CPHD1 (613038).
Diabetes, deafness, developmental delay, and short stature syndrome
MedGen UID:
1845412
Concept ID:
C5882732
Disease or Syndrome
Diabetes, deafness, developmental delay, and short stature syndrome (DDDS) is characterized by childhood-onset autoantibody-negative diabetes mellitus and bilateral sensorineural deafness, as well as short stature, microcephaly, and developmental delay (Montaser et al., 2021).

Professional guidelines

PubMed

Mårin P, Krotkiewski M, Björntorp P
Eur J Med 1992 Oct;1(6):329-36. PMID: 1341460
Andreyko JL, Monroe SE, Jaffe RB
J Clin Endocrinol Metab 1986 Oct;63(4):854-9. doi: 10.1210/jcem-63-4-854. PMID: 2943756
Styne DM, Harris DA, Egli CA, Conte FA, Kaplan SL, Rivier J, Vale W, Grumbach MM
J Clin Endocrinol Metab 1985 Jul;61(1):142-51. doi: 10.1210/jcem-61-1-142. PMID: 3923027

Recent clinical studies

Etiology

Bergamini M, Dalla Volta A, Palumbo C, Zamboni S, Triggiani L, Zamparini M, Laganà M, Rinaudo L, Di Meo N, Caramella I, Bresciani R, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Mazziotti G, Berruti A
Elife 2024 Apr 24;13 doi: 10.7554/eLife.92655. PMID: 38656229Free PMC Article
Krysiak R, Kowalcze K, Okopień B
Pharmacology 2023;108(3):245-254. Epub 2023 Feb 15 doi: 10.1159/000528939. PMID: 36791677Free PMC Article
Krysiak R, Kowalcze K, Okopień B
Gynecol Obstet Invest 2022;87(6):373-380. Epub 2022 Dec 14 doi: 10.1159/000527365. PMID: 36516786
Karppinen JE, Törmäkangas T, Kujala UM, Sipilä S, Laukkanen J, Aukee P, Kovanen V, Laakkonen EK
Eur J Prev Cardiol 2022 Aug 5;29(10):1448-1459. doi: 10.1093/eurjpc/zwac060. PMID: 35930503
Harrison TNH, Chang RJ
Clin Endocrinol (Oxf) 2022 Sep;97(3):310-318. Epub 2022 Mar 14 doi: 10.1111/cen.14708. PMID: 35244287Free PMC Article

Diagnosis

Krysiak R, Kowalcze K, Okopień B
Gynecol Obstet Invest 2022;87(6):373-380. Epub 2022 Dec 14 doi: 10.1159/000527365. PMID: 36516786
Krysiak R, Szkróbka W, Bednarska-Czerwińska A, Okopień B
Fundam Clin Pharmacol 2021 Apr;35(2):466-472. Epub 2020 Sep 10 doi: 10.1111/fcp.12600. PMID: 32813271
Ramírez-Expósito MJ, Martínez-Martos JM, Dueñas-Rodríguez B, Navarro-Cecilia J, Carrera-González MP
Breast Cancer Res Treat 2020 Aug;182(3):751-760. Epub 2020 Jun 6 doi: 10.1007/s10549-020-05723-1. PMID: 32506336
McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Kaaks R, Rinaldi S, Helzlsouer KJ
Int J Cancer 2009 Aug 1;125(3):674-9. doi: 10.1002/ijc.24406. PMID: 19444906Free PMC Article
Vihko RK, Apter DL
Cancer Surv 1986;5(3):561-71. PMID: 3555783

Therapy

Bergamini M, Dalla Volta A, Palumbo C, Zamboni S, Triggiani L, Zamparini M, Laganà M, Rinaudo L, Di Meo N, Caramella I, Bresciani R, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Mazziotti G, Berruti A
Elife 2024 Apr 24;13 doi: 10.7554/eLife.92655. PMID: 38656229Free PMC Article
Krysiak R, Kowalcze K, Okopień B
Pharmacology 2023;108(3):245-254. Epub 2023 Feb 15 doi: 10.1159/000528939. PMID: 36791677Free PMC Article
Krysiak R, Kowalcze K, Okopień B
Gynecol Obstet Invest 2022;87(6):373-380. Epub 2022 Dec 14 doi: 10.1159/000527365. PMID: 36516786
Harrison TNH, Chang RJ
Clin Endocrinol (Oxf) 2022 Sep;97(3):310-318. Epub 2022 Mar 14 doi: 10.1111/cen.14708. PMID: 35244287Free PMC Article
Krysiak R, Szkróbka W, Bednarska-Czerwińska A, Okopień B
Fundam Clin Pharmacol 2021 Apr;35(2):466-472. Epub 2020 Sep 10 doi: 10.1111/fcp.12600. PMID: 32813271

Prognosis

Ramírez-Expósito MJ, Martínez-Martos JM, Dueñas-Rodríguez B, Navarro-Cecilia J, Carrera-González MP
Breast Cancer Res Treat 2020 Aug;182(3):751-760. Epub 2020 Jun 6 doi: 10.1007/s10549-020-05723-1. PMID: 32506336
Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Macis D, Puccio A, Sandri MT, Gulisano M, Formelli F, Decensi A
Breast Cancer Res Treat 2013 Dec;142(3):569-78. Epub 2013 Nov 17 doi: 10.1007/s10549-013-2768-7. PMID: 24241787
Salmassi A, Mettler L, Jonat W, Buck S, Koch K, Schmutzler AG
Fertil Steril 2010 Jan;93(1):116-23. Epub 2008 Nov 8 doi: 10.1016/j.fertnstert.2008.09.083. PMID: 18996518
McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Kaaks R, Rinaldi S, Helzlsouer KJ
Int J Cancer 2009 Aug 1;125(3):674-9. doi: 10.1002/ijc.24406. PMID: 19444906Free PMC Article
Gougeon A
Rev Epidemiol Sante Publique 2005 Nov;53 Spec No 2:2S37-45. PMID: 16471143

Clinical prediction guides

Bergamini M, Dalla Volta A, Palumbo C, Zamboni S, Triggiani L, Zamparini M, Laganà M, Rinaudo L, Di Meo N, Caramella I, Bresciani R, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Mazziotti G, Berruti A
Elife 2024 Apr 24;13 doi: 10.7554/eLife.92655. PMID: 38656229Free PMC Article
Krysiak R, Kowalcze K, Okopień B
Pharmacology 2023;108(3):245-254. Epub 2023 Feb 15 doi: 10.1159/000528939. PMID: 36791677Free PMC Article
Krysiak R, Kowalcze K, Okopień B
Gynecol Obstet Invest 2022;87(6):373-380. Epub 2022 Dec 14 doi: 10.1159/000527365. PMID: 36516786
Bergadá I, Bergadá C, Campo S
J Pediatr Endocrinol Metab 2001 Apr;14(4):343-53. doi: 10.1515/jpem.2001.14.4.343. PMID: 11327369
Jenkin G, McFarlane JR, de Kretser DM
Reprod Fertil Dev 1995;7(3):323-31. doi: 10.1071/rd9950323. PMID: 8606941

Recent systematic reviews

Zhao L, Pang A
Front Endocrinol (Lausanne) 2020;11:428. Epub 2020 Aug 11 doi: 10.3389/fendo.2020.00428. PMID: 32849258Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...